Fundraising Fox
NVIGEN
Sunnyvale, US · Founded 2011 · 12 employees on LinkedIn · 1 known investors
Find your way into NVIGEN
Sign up to see every warm intro you have to NVIGEN
- Paths you didn't know you had: your email and LinkedIn already hold routes to the NVIGEN team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
NVIGEN develops multifunctional, biodegradable magnetic nanoparticles (nanobeads) and related assays for the biomedical research and diagnostics community, supporting applications such as NGS sample preparation, DNA/RNA/protein/exosome/cell isolation, liquid-biopsy immunodiagnostics, drug delivery, and cell therapy. It also offers precision-medicine biomarker profiling and single-cell RNA sequencing products for cancer detection and personalized therapy.
Founders & leadership
NVIGEN was founded in 2011 by Aihua Fu.
Board
Investors · 1
How we know: a partner's Signal profile · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$1.1M disclosed across 1 round · 2014
▶$1.1MraisedMar 2014 · 13 investors · BiotechnologyRule 506(b)
- Xiangdong JinExecutive Officer
- Guoliang YuDirector
- Aihua FuExecutive Officer, Director, Promoter
- Offering amount
- $1.5M
- Amount sold
- $1.1M
- First sale
- Mar 2014
- Incorporated
- Corporation, California, 2011
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $275.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $201.2K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does NVIGEN do?
- NVIGEN develops multifunctional, biodegradable magnetic nanoparticles (nanobeads) and related assays for the biomedical research and diagnostics community, supporting applications such as NGS sample preparation, DNA/RNA/protein/exosome/cell isolation, liquid-biopsy immunodiagnostics, drug delivery, and cell therapy. It also offers precision-medicine biomarker profiling and single-cell RNA sequencing products for cancer detection and personalized therapy.
- Who founded NVIGEN?
- NVIGEN was founded by Aihua Fu in 2011.
- Who are NVIGEN's investors?
- NVIGEN's investors include Foothill Ventures.
- How much funding has NVIGEN raised?
- NVIGEN has disclosed $1.1M raised across 1 round.
- Where is NVIGEN headquartered?
- NVIGEN is headquartered in Sunnyvale, US.